Lōkahi Therapeutics Launches Qare™ Health Platform for GLP-1 Medications

Lōkahi Therapeutics, a subsidiary of Glucotrack, Inc., has launched Qare™, a new comparative health platform designed to evaluate treatment outcomes by comparing patient experiences across different medications within the same therapeutic class, specifically for GLP-1 medications. The platform becomes publicly available on October 14.